1171921-06-4

Basic information

• Product Name: (5-Cyclopropyl-2-methyl-pyrazol-3-yl)methanol
• Synonyms: (5-Cyclopropyl-2-methyl-pyrazol-3-yl)methanol;(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)methanol
• CAS NO: 1171921-06-4
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.19368
• Mol File: 1171921-06-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (5-Cyclopropyl-2-methyl-pyrazol-3-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (5-Cyclopropyl-2-methyl-pyrazol-3-yl)methanol(1171921-06-4)
• EPA Substance Registry System: (5-Cyclopropyl-2-methyl-pyrazol-3-yl)methanol(1171921-06-4)

Safety Data

• Hazardous Substances Data: 1171921-06-4(Hazardous Substances Data)

Usage

Description

(5-Cyclopropyl-2-methyl-pyrazol-3-yl)methanol is a chemical compound with a molecular formula C9H12N2O, belonging to the pyrazole derivatives. It features a cyclopropyl and a methyl group, and the presence of a hydroxyl group allows for further derivatization to create new compounds with specific properties. (5-Cyclopropyl-2-methyl-pyrazol-3-yl)methanol holds potential in medicinal chemistry, particularly in drug discovery and development, and can also serve as a building block for synthesizing a variety of organic molecules.

Uses

Used in Medicinal Chemistry:
(5-Cyclopropyl-2-methyl-pyrazol-3-yl)methanol is used as a compound in medicinal chemistry for its potential role in drug discovery and development. Its unique structure and properties make it a valuable candidate for creating new pharmaceuticals.
Used in Organic Synthesis:
In the field of organic chemistry, (5-Cyclopropyl-2-methyl-pyrazol-3-yl)methanol is used as a building block for the synthesis of various organic molecules. The presence of the hydroxyl group in its structure facilitates the creation of new compounds with desirable characteristics.
Used in Research Applications:
Due to its unique structure and properties, (5-Cyclopropyl-2-methyl-pyrazol-3-yl)methanol is also utilized in research applications, where it can contribute to the advancement of scientific knowledge and the development of novel chemical processes or materials.

Upstream product

• 21080-80-8 ethyl 4-cyclopropyl-2,4-dioxobutanoate 
• 133261-11-7 ethyl 3-cyclopropyl-1-methyl-1H-pyrazole-5-carboxylate 
• 765-43-5 Cyclopropyl methyl ketone 

Downstream Products

• 1354198-66-5 2-((3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)methyl)-6-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 

Relevant articles and documents

Discovery of (10 R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17- tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]- benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations

Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung carcinoma patients, progression during treatment eventually develops. Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation. In addition, some patients progress due to cancer metastasis in the brain. Using structure-based drug design, lipophilic efficiency, and physical-property-based optimization, highly potent macrocyclic ALK inhibitors were prepared with good absorption, distribution, metabolism, and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability. These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clinically reported ALK kinase domain mutations. Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms. This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.